Golgi Protein for HCC Diagnosis

This case-control study was conducted on 90 patients who were equally divided into two groups. Group 1 included 45 patients with HCV-related chronic liver disease without clinical or radiological evidence of HCC (control group), and Group 2 included 45 patients diagnosed to have HCC by Triphasic abdominal CT (patient group). Serum AFP and GP73 were measured using ELISA technique

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Screening for Hepatocellular Carcinoma

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients were older than 18 years.

Exclusion criteria

patients with hepatic focal lesions not due to HCC such as Hemangioma, Hepatic cyst, and liver metastases; patients infected with HIV; patients with any autoimmune disease; or patients with metastatic disease.

Treatment and study plan

Serum Golgi Protein 73

Diagnostic Test

Serum test

Primary outcomes

Golgi protein correlated with presence of HCC

Time frame: within one year

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

Golgi Protein 73 for Diagnosis of HCC in Egyptian Patients

Important dates

Study start: 2014
Primary completion: 2015
Study completion: 2015
First posted: Feb 1, 2017
Registry last updated: Feb 1, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.